GSK, Yale partner to develop new drugs targeting disease-causing proteins
GlaxoSmithKline (NYSE:GSK) hopes to develop a new class of medicines through a new drug discovery partnership with Yale University. The collaboration will build on Yale’s research into ways to break down disease-causing proteins. The technology, called proteolysis-targeting chimeric molecules or PROTACs, leads disease-causing proteins to the part of a cell where they can be destroyed. […]